Pathogenetic approach to the treatment of functional disorders of the gastrointestinal tract and their intersection: Results of the Russian Observation Retrospective Program COMFORT

Abstract Background The aim of this study was to investigate the efficacy and safety of the novel complex drug, consisting of released-active form of antibodies to S-100 protein, tumor necrosis factor-α and histamine, (Kolofort) under outpatient conditions in patients with functional dyspepsia (FD), irritable bowel syndrome (IBS), and their combination. Methods The subject of the observational noninterventional retrospective program was the data of 14,362 outpatient records of patients with diagnosed FD, IBS, and/or their combination who received the drug Kolofort in monotherapy for 12 weeks, 2 tablets twice a day. To assess the presence and severity of symptoms of functional disorders of the gastrointestinal tract (FD GIT), a questionnaire “7*7” developed by a working group from the Russian Gastroenterological Association was used. The evaluated parameters included the proportion of patients: who had a reduction in the number of points by 50% or more; who have decreased the severity category of the condition; who have switched to the “healthy” and “borderline ill” severity categories;and the change in the number of points in domains 1–7. Results The final efficacy analysis included data from 9,254 patients. A decrease in the number of points by 50% or more was observed in 80.45% of patients with FD, 79.02% of patients with IBS, and in 83% of patients with both IBS and FD. A decrease in the severity category of the condition at the end of therapy was noted in 93.35% of patients with FD, in 93.80% of cases in patients with IBS, and in 96.17% of cases in patients with a combination of IBS and FD.A total of 94 adverse events (AEs) were reported in 80 patients (0.65%). Conclusion The COMFORT program has demonstrated the positive effect of treatment in the majority of patients with IBS and FD and their combination in real clinical practice.

Download Full-text

Pathogenetic approach to the treatment of functional disorders of the gastrointestinal tract and their intersection: Results of the Russian Observation Retrospective Program COMFORT

10.21203/rs.2.13285/v2 ◽

2019 ◽

Author(s):

Vladimir Ivashkin ◽

Elena Poluektova ◽

Alexey Glazunov ◽

Mikhail Putilovskiy ◽

Oleg Epstein

Keyword(s):

Gastrointestinal Tract ◽

Active Form ◽

The Novel ◽

Functional Disorders ◽

Efficacy Analysis ◽

Combination Methods ◽

S 100 ◽

Effect Of Treatment ◽

Irritable Bowel ◽

Factor Α

Download Full-text

Pathogenetic approach to the treatment of functional disorders of the gastrointestinal tract and their intersection: results of the Russian observation retrospective program COMFORT

BMC Gastroenterology ◽

10.1186/s12876-019-1143-5 ◽

2019 ◽

Vol 20 (1) ◽

Cited By ~ 1

Author(s):

Vladimir T. Ivashkin ◽

Elena A. Poluektova ◽

Alexey B. Glazunov ◽

Mikhail A. Putilovskiy ◽

Oleg I. Epstein

Keyword(s):

Active Form ◽

Functional Gastrointestinal Disorders ◽

The Novel ◽

Efficacy Analysis ◽

S 100 ◽

Lower Severity ◽

Effect Of Treatment ◽

Irritable Bowel ◽

Factor Α ◽

Positive Effect

Abstract Background The aim of this study was to investigate the efficacy and safety of the novel complex drug, consisting of released-active form of antibodies to S-100 protein, tumor necrosis factor-α and histamine, (Kolofort) under outpatient conditions in patients with functional dyspepsia (FD), irritable bowel syndrome (IBS), and FD-IBS overlap. Methods The subjects of the observational noninterventional retrospective program were the data of 14,362 outpatient records of patients with diagnosed FD, IBS, and/or overlap, who were observed by gastroenterologists from November 01, 2017, through March 30, 2018, who received the drug Kolofort in monotherapy for 12 weeks, 2 tablets twice a day. To assess the presence and severity of symptoms of functional gastrointestinal disorders (FGID), the “7*7” questionnaire developed by a working group from the Russian Gastroenterological Association was used. The evaluated parameters included the proportion of patients: who had a 50% or more reduction in the total score; who have switched to the less severe category of the condition; who have switched to the “healthy” or “borderline ill” severity categories; and the change in the score in domains 1–7. Results The final efficacy analysis included data from 9254 patients. A decrease in the total score by 50% or more was observed in 80.45% of patients with FD, 79.02% of patients with IBS, and in 83% of patients with both IBS and FD. Switch to a lower severity category of the condition at the end of therapy was noted in 93.35% of patients with FD, in 93.80% of cases in patients with IBS, and in 96.17% of cases in patients with a combination of IBS and FD. A total of 94 adverse events (AEs) were reported in 80 patients (0.65%). Conclusion The COMFORT program has demonstrated the positive effect of treatment in the majority of patients with IBS and FD and their combination in real clinical practice.

Download Full-text

Quality of Life and Level of Physical Activity In Students with and without Symptoms of Functional Dyspepsia and Irritable Bowel Syndrome Surveyed with Questionnaire “7×7” (7 Symptoms Per 7 Days)

Russian Journal of Gastroenterology Hepatology Coloproctology ◽

10.22416/1382-4376-2020-30-3-36-41 ◽

2020 ◽

Vol 30 (3) ◽

pp. 36-41

Author(s):

T. V. Zhestkova

Keyword(s):

Quality Of Life ◽

Physical Activity ◽

Irritable Bowel Syndrome ◽

Gastrointestinal Tract ◽

Functional Dyspepsia ◽

Functional Disorders ◽

Men And Women ◽

Moderate Severity ◽

Irritable Bowel

Aim. Assessment of the quality of life and physical activity level in students with and without symptoms of functional dyspepsia (FD) and irritable bowel syndrome (IBS) according to questionnaire “7×7” (7 symptoms per 7 days).Materials and methods. Symptoms of FD and IBS were surveyed using the “7×7” questionnaire. Level of physical activity was evaluated according to the short IPAQ, and quality of life — to WAM questionnaires.Results. The study surveyed 92 students aged 20.7 ± 0.2 years (56 men and 36 women). We report borderline manifestations of functional disorders of the gastrointestinal tract (GIT) in 51.1 %, and FD and/or IBS symptoms of mild to moderate severity in 23.9 % of respondents. Symptoms of FD and/or IBS were equally common in men and women. Severity of FD and/or IBS symptoms was rated 4 [[3; 7] in men and 4 [[4; 11] in women (p = 0.25). Physical activity of 57.6 % in students corresponded to a moderate level. Healthy students were more likely to exhibit higher physical activity than individuals with FD and/or IBS symptoms, 56.5 and 31.9 %, respectively (p = 0.04). The level of wellbeing and severity of FD and/or IBS symptoms correlated negatively (r = –0.28, p = 0.01). Wellbeing and mood correlated directly with physical activity, r = 0.33, p = 0.001 and r = 0.27, respectively (p = 0.01).Conclusions. 1. Symptoms of FD and/or IBS occur widely among students and equally in men and women. Functional disorders of the gastrointestinal tract of mild to moderate severity occur in 23.9 % of students, with borderline symptoms registered with every second individual. 2. Healthy students significantly more often exhibited higher physical activity compared to individuals with FD and/or IBS symptoms of varying severity in the ratios of 56.5 and 31.9 % (p = 0.04). 3. Severity of FD and/or IBS in students negatively correlates with the wellbeing component of quality of life (r = –0.28, p = 0.01).

Download Full-text

THE FUNCTIONAL STATUS OF GASTROINTESTINAL TRACT AND FEATURES OF OUTCOMES IN ACUTE INTESTINAL INFECTIONS

Epidemiology and Infectious Diseases (Russian Journal) ◽

10.17816/eid40674 ◽

2012 ◽

Vol 17 (3) ◽

pp. 56-59

Author(s):

M. S. Grigorovich

Keyword(s):

Irritable Bowel Syndrome ◽

Gastrointestinal Tract ◽

Digestive System ◽

High Rate ◽

Lactase Deficiency ◽

Functional Disorders ◽

Intestinal Infections ◽

Reactive Changes ◽

Irritable Bowel

The significance of the problem of acute intestinal infections (AII) to date is associated with both their prevalence and high rate of adverse effects in the outcome of the disease. In modern literature there is enough information about the frequent occurrence in AII patients microbiota disorders, immune system imbalances, identifying signs of reactive changes ofpancreatic tissue and functional disorders of biliary tract, lactase deficiency, long-term disorders of functional activity of the digestive system. The data about AII as one of the factors of forming the gastrointestinal tract pathology, including irritable bowel syndrome have been accumulated.

Download Full-text

Irritable bowel syndrome and biliary tract pathology. Clinical analysis

Medical Council ◽

10.21518/2079-701x-2020-15-28-38 ◽

2020 ◽

pp. 28-38

Author(s):

T. E. Polunina

Keyword(s):

Irritable Bowel Syndrome ◽

Abdominal Pain ◽

Gastrointestinal Tract ◽

Biliary Tract ◽

Emotional Health ◽

Biological Marker ◽

Recurrent Abdominal Pain ◽

Clinical Analysis ◽

Functional Disorders ◽

Irritable Bowel

Irritable bowel syndrome (IBS) – a recurrent functional disorder of the gastrointestinal tract (GIT), the main symptom of which is abdominal pain necessarily associated with a change in intestinal function. IBS is a functional intestinal disorder in which recurrent abdominal pain is associated with a defecation act and a change in the frequency or shape of the stool. The diagnosis of IBS remains exclusively clinical. The difficulty in studying IBS, especially from the perspective of its epidemiology, is that there is still no universal and specific biological marker. Very often patients complain about symptoms typical for several functional disorders, in particular, biliary tract pathology and IBS. The article discusses the multi-component causes and mechanisms of IBS formation, which are also present in other functional gastrointestinal tract diseases. Patients with IBS often have functional disorders of the biliary tract (FDBT) that are not associated with organic pathology. There are no reliable differences in the frequency and nature of FDBT in patients with IBS, depending on its current variant - with constipation or diarrhea prevalence. As a result, the treatment of patients with IBS remains a challenge, and the recurrence of the disease depends on the state of psycho-emotional health, the presence of overlap syndrome in most cases. The article presents the main international criteria for diagnostics of IBS. The main approaches to the treatment of IBS are considered. Good results in the treatment of IBS are observed when using drugs that affect the complex of pathophysiological mechanisms of the disease. This is confirmed in the article by a clinical case study. The prescription of the Sparex drug for pain relief in a patient with IBS and FDBT is justified by the fact that it not only eliminates pain, but also improves the rheological properties of bile, typical for overlap “IBS-FDBT” syndrome.

Download Full-text

Low histamine resistance syndrome: is it cause or result of gastrointestinal tract pathology?

Experimental and Clinical Gastroenterology ◽

10.31146/1682-8658-ecg-179-7-152-157 ◽

2020 ◽

pp. 152-157

Author(s):

M. S. Turchina ◽

Z. V. Karaseva

Keyword(s):

Gastrointestinal Tract ◽

Allergic Diseases ◽

Biologically Active ◽

Functional Disorders ◽

Medical Practitioners ◽

Anaphylactoid Reactions ◽

The Russian Federation ◽

Irritable Bowel ◽

Active Substances

Currently, in the Russian Federation, as well as throughout the world, there is an increase in allergic diseases, including an increase in the number of gastrointestinal manifestations of allergies. Moreover, along with Ig-E-mediated reactions, anaphylactoid reactions occur due to the excessive release of histamine and other biologically active substances from mast cells. These pathological processes can contribute to exacerbation of functional disorders of the gastrointestinal tract, enhancing subclinical inflammation of the mucous membrane, contributing to the development of visceral hypersensitivity and gastrointestinal motility. At the same time, most medical practitioners do not pay due attention to the possible impact of allergic and pseudo-allergic reactions on the course of irritable bowel syndrome and functional dyspepsia. At the same time, it is necessary to take into account that in the case of the syndrome of low resistance to histamine in most patients, the introduction of restrictions on the diet is sufficient and there is no need to prescribe excess drugs. Given the widespread prevalence of functional disorders of the gastrointestinal tract and their significant impact on the quality of life of patients, it is necessary to search for new methods of prevention and treatment of this group of pathological conditions.

Download Full-text

New ideas about functional intestinal disorders and the place of modern probiotics in their treatment

Medical Council ◽

10.21518/2079-701x-2018-21-126-131 ◽

2019 ◽

pp. 126-131 ◽

Cited By ~ 1

Author(s):

О. N. Minushkin

Keyword(s):

Irritable Bowel Syndrome ◽

Gastrointestinal Tract ◽

Effective Treatment ◽

Intestinal Flora ◽

Functional Disorders ◽

Pathogenetic Mechanisms ◽

New Ideas ◽

Irritable Bowel

The article presents new definitions of functional disorders of the gastrointestinal tract (Roman criteria IV) and irritable bowel syndrome (from the section of functional disorders of the intestine). Modern pathogenetic links of IBS and changes in intestinal flora as one of the main pathogenetic mechanisms are considered. The use of probiotics in the treatment of IBS is considered and the data of effective treatment of 520 patients (IBS-diarrhea: 120 children and 400 adults) with the new multiprobiotic Bac-Set are presented.

Download Full-text

Clinical and Serological Biomarkers of Treatment’s Response in Multiple Sclerosis Patients Treated Continuously with Interferonβ-1b for More than a Decade

CNS & Neurological Disorders - Drug Targets ◽

10.2174/1871527317666180917095256 ◽

2018 ◽

Vol 17 (10) ◽

pp. 780-792 ◽

Cited By ~ 5

Author(s):

Laura Iulia Bărcuţean ◽

Andreea Romaniuc ◽

Smaranda Maier ◽

Zoltan Bajko ◽

Anca Moţăţăianu ◽

...

Keyword(s):

Multiple Sclerosis ◽

Demographic Data ◽

Active Form ◽

Positive Influence ◽

Serum Samples ◽

Disability Score ◽

Positive Correlations ◽

Multiple Sclerosis Patients ◽

Factor Α ◽

Serological Biomarkers

Introduction: We evaluated the peripheral immune panel of Multiple Sclerosis (MS) patients treated for more than 10 years with interferon-beta1b (IFNβ-1b) and aimed to identify possible biomarkers of treatment response. Material and Methods: Serum samples from 70 MS patients treated with IFNβ-1b more than a decade were analysed for 15 cytokines, that were correlated with the disability score, annual relapse ratio (ARR): the total number of relapses-ARR_0, relapse on treatment-ARR_1 and demographic data. Two groups were defined based on the levels of disability, calculated using the Expanded Disability Status Scale (EDSS): G1 – recurrent-remissive and G2 – secondary-progressive. Furthermore, we split the patients based on gender (G1_f, G1_m, G2_f, G2_m). Results: The ARR was reduced after treatment was instituted. We found positive correlations between IL_25 and EDSS in G1_f and G2_f, tumor necrosis factor α (TNFα) and ARR_1 and ARR_0 in G1, and IL_17F with ARR_1. Negative correlations were for IL_25 and ARR_0 and ARR_1. SCD40L intensely positively correlated with IL_31 in G1 and G2. Conclusion: After more than a decade of treatment, IFNβ-1b offers good results by reducing relapses and slowing disability progression. Several biomarkers can be used to assess the patient’s response. High levels of IL_17 and TNFα will indicate a more active form of the disease. IL-25 may exert a positive influence in male MS patients and should be considered for future studies, together with the co-modulation between sCD40L and IL_31. Our method allowed us to screen the peripheral immune panel and can be used for assessing the peripheral levels of the above-mentioned cytokines.

Download Full-text

COVID-19 Vaccination: From Interesting Agent to the Patient

Vaccines ◽

10.3390/vaccines9020120 ◽

2021 ◽

Vol 9 (2) ◽

pp. 120

Author(s):

Anis Daou

Keyword(s):

Central Nervous System ◽

Nervous System ◽

Gastrointestinal Tract ◽

Circulatory System ◽

The Novel ◽

Lead Compound ◽

Fda Approval ◽

The World ◽

The Central Nervous System ◽

Novel Coronavirus

The vaccination for the novel Coronavirus (COVID-19) is undergoing its final stages of analysis and testing. It is an impressive feat under the circumstances that we are on the verge of a potential breakthrough vaccination. This will help reduce the stress for millions of people around the globe, helping to restore worldwide normalcy. In this review, the analysis looks into how the new branch of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) came into the forefront of the world like a pandemic. This review will break down the details of what COVID-19 is, the viral family it belongs to and its background of how this family of viruses alters bodily functions by attacking vital human respiratory organs, the circulatory system, the central nervous system and the gastrointestinal tract. This review also looks at the process a new drug analogue undergoes, from (i) being a promising lead compound to (ii) being released into the market, from the drug development and discovery stage right through to FDA approval and aftermarket research. This review also addresses viable reasoning as to why the SARS-CoV-2 vaccine may have taken much less time than normal in order for it to be released for use.

Download Full-text